Clinical trial
Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed in 2007 the company name to Oncothyreon Inc. Oncothyreon is now located in Seattle, Washington, USA. Reformed to SGEN after M&amp;A in March 2018.